SBRT for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-01-31

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Single-institution retrospective analysis for predictive factors of prostate cancer patients presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between January 2010 and July 2015.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence

NCT03438552

Local Recurrence of Malignant Tumor of Prostate

ACTIVE_NOT_RECRUITING NA

A Phase I-II Study on Stereotactic Body Radiotherapy in 3 Fractions for Low/Int Risk Prostate Cancer

NCT02623647

Prostate Cancer

UNKNOWN NA

Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response

NCT06831032

Prostate Adenocarcinoma Iliac Nodal Disease Para-aortic Lymph Node Metastasis +2 more

NOT_YET_RECRUITING NA

A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer

NCT02254746

Prostate Adenocarcinoma

COMPLETED NA

Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

NCT04974671

Renal Cell Carcinoma Metastatic Renal Cell Carcinoma Oligoprogressive +1 more

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Single-institution retrospective analysis of consecutive prostate cancer patients after definitive primary treatment, without local recurrence, presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between January 2010 and July 2015.

Endpoints of interest are biochemical response rate (defined as a reduction by at least 10% of the initial PSA value), time to biochemical recurrence (TBR) (defined as the time interval from SBRT until second PSA rise), and time interval between SBRT and ADT start. Univariate analysis is used to identify prognostic factors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer Recurrent Prostate Cancer Lymph Node Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cyberknife Radiation Therapy

Stereotactic Radiotherapy of lymphnode recurrence after prostatectomy +/- salvage radiotherapy

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* histologically proven diagnosis of prostate cancer
* Radical prostatectomy (± salvage radiotherapy)
* PSA relapse (defined by two consecutive rising PSA values \>0.2 ug/l)
* one to three lymphnodes positive on Choline-PET
* no recurrence in prostatic bed on Choline-PET
* WHO performance status of 0-1
* no previous chemotherapy or ADT for prostate cancer.